TGF-β receptor 1 Anshul Badhwar. Transforming Growth Factor β - receptor type I / ALK5 Serine/Threonine kinase receptor.

Slides:

Advertisements

Similar presentations

The Notch-  -Secretase Pathway. Notch activation involves the proteolytic cleavage of the Notch ligand/receptor complex by  -secretase to release the.

Advertisements

Stem Cells and Cell Signaling

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

BMP Receptor 1 : Juvenile Polyposis (Colon Cancer) Cecily Johnson Biology 169 March 24, 2005.

Notch1 and pre-T-cell Acute Lymphoblastic Leukemia (T-ALL) by Lindsey Wilfley.

SMAD4/DPC4: A Tumor Suppressor James Brooks March 23 rd, 2006.

Wilms’ Tumor Nephroblastoma Affects 1:10,000 children ~8% of all pediatric Malignancies 80% of these tumors can be successfully treated.

Regulated Splicing Changes are Associated with Tumor Type and Grade Exon specific array from 3 lymphoma cell lines (IV, IVb and III) and non-tumor B cell.

Transforming Growth Factor β Receptor Type II Tina Morris

PDGF β Receptor. Protein 1106 amino acid protein Weinberg Fig 5.10.

Copyright (c) by W. H. Freeman and Company Chapter 24 Cancer.

MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.

Transforming Growth Factor-Beta Receptor 2 TGF-β receptor 2

The Effects of Histone Deacetylase Inhibitor on the Expression of TGF-  Sensitivity in HKc/DR Cells John A. Mkpa Claflin University/University of South.

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Lung Cancer slide presentation is not an independent educational.

Chapter 20 oncogene, anti-oncogene and growth factor The biochemistry and molecular biology department of CMU.

Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness Gary Xiao, Ph.D. Professor and Director School of Pharmaceutical Science & Technology.

TGF-β Receptor I/ALK5: An Attractive Therapeutic Target in Tumor Development By Jake Bridgers.

Phase 1 Study of ACE-041, a First-in-Class Inhibitor of Vascular Development in Patients with Advanced Solid and Hematologic Tumors N. G. Borgstein 1,

IGF-1R: A key linker between chemoresistance and cancer stem cells in epithelial ovarian cancer cells Ram Kumar Singh, Ankit Jinager, Ajit Dhadwe, Abhijit.

Smad4 in Colon & Pancreatic Cancers

BMPR1A Bone Morphogenetic Protein Receptor 1 A (Juvenile Polyposis & Colon Cancer) Hallie Wieters.

Inflammation Due To RA.

oncogene, anti-oncogene and growth factor

VALERIE H. CHEN Transforming Growth Factor (TGF) Beta Receptor 2 and Gastric Cancer.

1. Epithelial Mesenchymal Transition ( EMT ) 2 3.

Gene Sleuthing Lorraine Sartori Majid Masso Paul R. McCreary.

DEMI DABOR-ALLOH TGF-β Receptor II and Gastric Cancer.

Fibroblast Growth Factors (FGFs)

BMP receptor1A Presented by Jena Buchan

Cancer Cancer- a malignant tumor; the result of abnormal cell proliferation. Regulation of Cell Division –Tumor Supressor Genes Genes that inhibit cell.

TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.

Relationship Between STAT3 Inhibition and the Presence of p53 on Cyclin D1 Gene Expression in Human Breast Cancer Cell Lines Introduction STAT3 and p53.

TGFβ-Receptor 1/ALK5 NEIL MEHTA BIOL

Leila Kokabee*, Xianhui Wang, Cheryl Eifert, Douglas S. Conklin

Fig. 4. Effects of lobeglitazone (Lobe) on the transforming growth factor β (TGF-β)/Smad3 signaling pathway in kidney cell lines. (A) Effects of Lobe on.

A model for the role of ALK-1 and endoglin in normal angiogenesis

Cell Physiol Biochem 2017;44:1867– DOI: /

The Role of SMAD4 (DPC4) in Cancer

Bone Morphogenetic Protein Receptor 1A (BMPR1A) and Juvenile Polyposis Syndrome Cara Davidson March 18, 2004.

Fibroblast Growth Factor 3 (FGF3) int-2

Molecular Basis Of Cancer

SDHB deficiency promotes TGFβ-mediated invasion and metastasis of colorectal cancer through transcriptional repression complex SNAIL1-SMAD3/4 Haiyu Wang,

PTEN (a.k.a. MMAC1 and TEP1) and Cowden’s Disease

Relationship between Genotype and Phenotype

PTEN Tumor Suppressor and Cancer

Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo Markus Wagner, Martha E. Lopez, Mitch.

Volume 116, Issue 5, Pages (May 1999)

Reactive oxygen species inhibit miR‐199a and miR‐125b expression levels in vitro and in vivo. Reactive oxygen species inhibit miR‐199a and miR‐125b expression.

BMP Receptor 1a and Juvenile Polyposis Syndrome

Transgenic Mouse Technology in Skin Biology: Generation of Complete or Tissue- Specific Knockout Mice Lukas Scharfenberger, Tina Hennerici, Gábor Király,

A. Woods, Ph. D. , D. Pala, M. Sc. , L. Kennedy, M. Sc. , S. McLean, B

Microarray analysis of phospho-Twist1–responsive genes.

Smad4 (Dpc4) in Colon Cancer

TGF-β Receptor I/ ALK-5 and Pancreatic and Biliary Cancer

Volume 12, Issue 4, Pages (October 2003)

Hdac3 deletion decreases AKT phosphorylation and tumor growth in Pten knockout prostate cancer Hdac3 deletion decreases AKT phosphorylation and tumor growth.

Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.

miR-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

EGFR and cetuximab sensitivity of SCCUAT

Vandetanib decreases tumor incidence and accumulation of HIF-2α, expression of c-Myc and growth factor receptors in the lung of hypoxic mice. Vandetanib.

Neoplasia lecture 7 Dr Heyam Awad FRCPath.

Targeting DCLK1 by miRNA-137.

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

miR-100 suppresses bladder cancer cell growth in vitro and in vivo.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

DEAR1 blocks TGF-β–induced anoikis resistance, and TGF-β and SMAD3 signal transduction. DEAR1 blocks TGF-β–induced anoikis resistance, and TGF-β and SMAD3.

Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.

CREB1 binds at the proximal region of the TGFB2 promoter and induces its transcriptional activation. CREB1 binds at the proximal region of the TGFB2 promoter.

Presentation transcript:

TGF-β receptor 1 Anshul Badhwar

Transforming Growth Factor β - receptor type I / ALK5 Serine/Threonine kinase receptor.

Transforming Growth Factor β - receptor type I Serine/Threonine kinase receptor. Involved in both tumor suppression and promotion.

Transforming Growth Factor β - receptor type I Serine/Threonine kinase receptor. Involved in both tumor suppression and promotion. Normal role in tissue regeneration, cell differentiation, embryonic development, growth inhibition and cell migration.

TGF- β Signal Transduction Pasche et. al

Knocking out the TGF- β Receptor Larsson et. al 2001

Knocking out the TGF- β Receptor Genotyping by PCR will produce a 350bp if TGF- β Receptor gene has been knocked out. If exon 3 has not been knocked out a 150bp band will show up.

TGF- β Knockout Mice TGF- β -/-  Embryonic Lethal at Day 10.5  Abnormal Vascular Development  Reduced Fibronectin Production (in vitro)  Insensitive to TGF- β growth inhibition. (in vitro)  Unresponsive to anti-migratory signals of TGF- β(in vitro) TGF- β +/-  Development and phenotype same as wildtype

Insensitivity to Growth Suppresion T3M4 Human Pancreatic Cell lines showed no response to TGF-Beta growth suppression Interestingly enough, sequencing analysis indicated that T3M4 cells do not harbor mutations in the TGFβ GRI or Smad4 genes.

Transfection of TGF-β receptor Suprisingly enough cells became responsive to TGF- β and underwent growth inhibition similar to wild type.

Connection to Human Cancers In Vivo many human pancreatic cancers express low levels of the TGF-beta receptor. 5% of all pancreatic tumors have the TGF-beta receptor mutated in some form. In Vitro many human pancreatic are often resistant to growth inhibition by the TGF-beta. TGF-βRI (ALK5) expression is decreased in a prostate, pancreatic and colon cancer cells.

Pancreatic Cancer Pancreatic cancer incredibly hard to treat Symptoms show up very late 99% fatality rate when diagnosed

References Baldwin, R. L., Friess, H., Yokoyama, M., Lopez, M. E., Kobrin, M. S., Büchler, M. W. and Korc, M., Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int. J. Cancer, 67, (1996). Larrsson J., Goumans M.J., Sjostrand L.J., Rooijen M.A., Ward D., Leveen P., Xu X., Dijke P., Mummery C., Karlsson S., Abnormal angiogenesis but intact hematopoietic potential in TGF- β type I receptor-deficient mice, EMBO, 20, (2001). Steiner, M. S. and Barrack, E. R., Transforming growth factor- overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol. Endocrinol., 6, (1992). Wagner M.,Kleeff J, Lopez M.E., Bockman I., Massaqué J., Korc M., Transfection of the type I TGF- β receptor restores TGF- β responsiveness in pancreatic cancer. Int. J. Cancer, 78, (1998)